Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

206.67B

Market cap206.67B

Price-Earnings ratio

10.67

Price-Earnings ratio10.67

Dividend yield

2.70%

Dividend yield2.70%

Average volume

12.33M

Average volume12.33M

High today

$46.15

High today$46.15

Low today

$45.15

Low today$45.15

Open price

$45.49

Open price$45.49

Volume

6.60M

Volume6.60M

52 Week high

$81.44

52 Week high$81.44

52 Week low

$35.12

52 Week low$35.12

NVO News

TipRanks 34m

Novo Nordisk’s CagriSema Trial Puts Next-Generation Obesity Strategy in Focus

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings...

Bloomberg 7h

The Novo Shadow Hanging Over Denmark’s Economy - Bloomberg.com

...

MarketWatch 22h

Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

Eli Lilly’s stock is on track for a record close after the drugmaker disclosed that one of the nation’s most powerful pharmacy-benefit managers will start cover...

Analyst ratings

57%

of 37 ratings

Buy

35.1%

Hold

56.8%

Sell

8.1%

More NVO News

Nasdaq 1d

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Key Points Eli Lilly is performing very well as a business right now, which should please shareholders. Novo Nordisk has fallen behind Eli Lilly in the GLP-1...

Seeking Alpha 1d

France to become first EU nation to cover weight-loss meds

France has become the first EU nation to reimburse weight loss medications, including blockbuster GLP-1s from Novo Nordisk (NVO) and Eli Lilly (LLY), with cover...

CNBC 1d

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. CVS Health on Thursday said it will re...

Simply Wall St 1d

Novo Nordisk Advances Oral Wegovy Lead As Investor Focus Shifts To Uptake

Novo Nordisk (NYSE:NVO) has gained a lead in oral anti obesity pills with its oral Wegovy following a positive opinion from the European Medicines Agency. Earl...

The Motley Fool 2d

Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Novo Nordisk (NVO +0.89%) pioneered weight loss medicines with Wegovy, an anti-obesity therapy that quickly became a hit. However, it lost its lead to Eli Lilly...

TipRanks 2d

Novo Nordisk to showcase new data from its cardiometabolic portfolio at ADA

The company states: “Novo Nordisk (NVO) announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientifi...

TipRanks 2d

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.